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Abstract:  
In this research we employed layered double hydroxide nanoparticles (LDHs) to simultaneously 
deliver an anticancer drug 5-fluorouracil (5-FU) and Allstars Cell Death siRNA (CD-siRNA) for 
effective cancer treatment. The strategy takes advantage of the LDH anion exchange capacity to 
intercalate 5-FU into its interlayer spacing and load siRNA on the surface of LDH nanoparticles. 
LDH nanoparticles have been demonstrated as an effective cellular delivery system for 5-FU and 
siRNA separately in this and other investigations. More excitedly, the combination of CD-siRNA 
and anticancer drug 5-FU with the same LDH particles significantly enhanced cytotoxicity to 
three cancer cell lines, e.g. MCF-7, U2OS and HCT-116, compared to the single treatment with 
either CD-siRNA or 5-FU. This result is probably a result of coordinate mitochondrial damage 
process. Thus, the strategy to co-deliver siRNA and an anticancer drug by LDHs has great 
potential to overcome the drug resistance and enhance cancer treatment.   
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1. Introduction 
Chemotherapy is one of most common cancer treatments in clinics. In most cases, the clinical 
responses show that the efficacy of chemotherapy is limited by the development of multidrug 
resistance (MDR) in cancer cells during a long period of treatment [1, 2]. To overcome the 
resistance, higher doses of toxic anticancer drugs are sometimes required, which can also kill 
healthy cells and result in adverse side effects on healthy organs [3]. Thus, the development of an 
effective strategy to overcome the multidrug resistance in chemotherapy remains a major 
challenge in the treatment of cancers.  
One strategy is to combine two different types of anticancer therapeutics for effective cancer 
treatment [6-8], for example, co-deliver 5-fluorouracil (5-FU) and small interfering RNAs 
(siRNAs). 5-FU has been used against cancers for over 40 years and acts principally as a 
thymidylate synthase inhibitor [4]. Drug resistance is a major issue in the clinical application of 
5-FU. siRNA molecules, in contrast, have emerged as a powerful tool to suppress tumor growth 
due to their properties to induce potent, persistent, and specific silencing of a broad range of 
genetic targets [5, 6]. Therefore, a combination of the anticancer drug 5-FU and siRNA for 
advanced cancer treatment could be an effective way to overcome MDR [7-9]. In recent years, 
several groups have reported significant improvements using combined cancer therapies. For 
example, Nakamura et al. reported that the combination of siRNA against Bcl-2 and 5-FU 
delivered by lipoplexes showed superior tumor inhibition compared to the monotherapy with 
either 5-FU or Bcl-2-siRNA [10]. More recently, Chen et al. found that mesoporous silica 
nanoparticles can been used to co-deliver doxorubicin with siRNA against Bcl-2 or p-
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glycoprotein, resulting in significantly increased cytotoxic effects on multidrug resistant cancer 
cells in vitro [11].  
Although the combination of chemotherapy and siRNA-based therapy for advanced cancer 
treatment has shown great promise, an ideal delivery system that can elegantly accommodate 
siRNAs and chemotherapeutic drugs and effectively co-deliver them to cancer cells would 
further enhance cancer treatment efficacy. Currently, liposomes and cationic core-shell 
nanoparticles [3, 12, 13] have been used to simultaneously deliver drugs and siRNAs into cancer 
cells, while the drug-siRNA-carrier system can be rationally designed to further improve anti-
cancer efficiency. It is our belief that layered double hydroxide (LDH) nanoparticles are one of 
the more effective carrier and delivery systems. 
Layered double hydroxides (LDHs), a family of anionic clay materials, are considered 
promising inorganic matrices for drug and gene delivery due to their unique properties, such as 
high layer charge density (2-5 mequiv/g), anion exchange property, low cytotoxicity, pH-
controlled release, good biocompatibility, tunable particle size, and protection of drugs and genes 
during the delivery process [14, 15]. LDHs consist of cationic brucite-like layers and interlayer 
anions with the general chemical composition M2+1-xM3+x(OH)2 (An-x/n)·yH2O, where M2+ and 
M3+ are divalent and typically trivalent metal cations respectively, An- an anion, and x the molar 
ratio of the trivalent to the total cations [16]. The anionic drugs and biomolecules (including 
genetic materials) can be easily exchanged with the interlayer anion An-, and are thus protected 
against enzymatic degradation. Recent studies have demonstrated that LDHs are an efficient 
carrier to deliver anionic anticancer drugs such as methotrexate (MTX) [17, 18] and 5-FU [19, 
20], and functional oligonucleotides, especially siRNAs [21, 22], for cancer treatment. Choy et al 
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reported that MTX delivered by LDHs significantly enhanced drug efficacy compared to free 
MTX in human osteosarcoma cells (HOS, SaOS-2 and MG-63) [23, 24]. In our previous studies, 
LDH-mediated siRNAs effectively silenced the target gene expressions [21, 22, 25]. It is clear 
that the single treatment by either anticancer drug or siRNA delivered by LDH nanoparticles can 
only achieve limited success in cancer treatment, while the co-delivery of anticancer drugs and 
siRNA that are elegantly combined with LDH nanoparticles would synergistically enhance the 
efficacy in cancer treatment. To our knowledge, there are no reports on simultaneously 
delivering a traditional anticancer drug and siRNA to cancer cells using LDH nanocarriers for 
enhanced cancer therapy.  
As illustrated in Scheme 1A, LDH nanocarriers first intercalate with 5-FU into the interlayers 
to form 5-FU/LDH nanohybrids, and then load CD-siRNA to form CD-siRNA-5-FU/LDH 
nanocomplexes via the electrostatic interactions between negatively charged siRNAs and 
positively charged 5-FU/LDH. In this work, we aimed to investigate whether 5-FU and CD-
siRNA can be efficiently co-delivered into the cancer cells by LDH nanocarriers and to what 
extent the combined treatment with 5-FU and CD-siRNA may enhance the suppression of cell 
growth compared to single treatment with either CD-siRNA/LDH or 5-FU/LDH alone.  
 
2. Materials and Methods 
2.1 Materials 
MgCl2·6H2O, AlCl3·6H2O, NaOH, 5-FU, bovine serum albumin, Tween 20, and lysis buffer 
were purchased from Sigma (USA). AllStars Cell Death siRNA (CD-siRNA) and AllStars 
negative controlled fluorescent siRNA AF 546 (CD-siRNA AF546) were purchased from 
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QIAGEN Pty. Ltd. (Vic, Australia). GelRed Nucleic acid gel stain was bought from Biotium Inc. 
(USA). Agarose, 25-bp dsDNA ladder mark, 0.25% Trypsin-EDTA (1X), PBS buffer 
(37mmol/L NaCl, 2.7 mmol/L KCl, 8.1 mmol/L Na2HPO4, and 1.47 mmol/L KH2PO4, pH 7.4), 
Tris-buffer and DMEM medium were obtained from Life Technologies Corporation (Australia). 
BD Pharmingen™ FITC Annexin V Apoptosis Detection Kit I was obtained from BD 
Biosciences (USA). A Bio-Rad DC Protein Assay kit was purchased from Bio-Rad Laboratories 
(CA). Mouse monoclonal anti-human Bcl-2 antibody and mouse monoclonal anti-human α-
tubulin antibody were bought from Bio-legend (CA). 
 
2.2 Preparation of 5-FU/LDH nanohybrids 
Mg2Al-LDH-Cl nanoparticles (LDH-Cl) were prepared using the co-precipitation-hydrothermal 
method reported previously [26], and 5-FU/Mg2Al-LDH-Cl (5-FU/LDH) nanohybrids were 
synthesized similarly. In brief, a mixture of 0.3 M MgCl2 and 0.1 M AlCl3 solution (10 mL) was 
quickly added to 40 mL of 0.15 M NaOH solution under vigorous stirring. After stirring for 10 
min, the LDH slurry was collected via centrifuge separation and re-suspended in 40 mL of 
solution containing a certain amount of 5-FU (neutralized with dilute NaOH solution, with pH of 
8-9) and shaken for 1 h at 37oC. The resultant suspension was separated, washed and then re-
suspended in 40 mL distilled water. The inhomogeneous suspension was transferred to an 
autoclave (stainless steel with a Teflon lining) and heated in an oven at 100 oC for 16 h. After 
hydrothermal treatment, a transparent, homogenous suspension containing 5-FU/LDH was 
obtained. The loading amount of 5-FU drug was determined using UV-Vis. The samples were 
marked as 5-FU(n)/LDH, where n equals  the exchange capacity of 5-FU in LDH-Cl samples.  
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2.3 Preparation of siRNA or dsDNA-5-FU/LDH nanohybrids 
A predetermined amount of dsDNA was added to a vial containing an appropriate amount of 5-
FU/LDH or LDH to make the dsDNA-5-FU/LDH or dsDNA/LDH with the mass ratio of 
dsDNA to LDH equal to 1:5, 1:10, 1:20 and 1:40, respectively. The mixture suspension was 
shaken via a vortex for 15 s and then kept still at room temperature for 1 h. CD-siRNA/LDH 
and CD-siRNA-5-FU/LDH nanohybrids were prepared in the same way with the mass ratio of 
CD-siRNA to LDH approximately 1:20 and 1:40, respectively.  
 
2.4 Physicochemical characterization 
The hydrodynamic particle size and the zeta potential of LDH and 5-FU/LDH nanohybrids were 
determined by dynamic light scattering (DLS). All measurements were carried out at 25 oC in a 
photon correlation spectroscopy (PCS, Nanosizer Nano ZS, MALVERN Instruments). Each 
parameter was measured in triplicate and the average value was calculated. Powder X-ray 
diffraction (XRD) patterns were recorded on a Rigaku Miniflex X-ray diffractometer with a 
variable slit width at a scanning rate of 2°/min with 2θ ranging from 2.5° to 80° using Co Kα 
radiation (λ=0.17902 nm). The LDH or 5-FU/LDH suspension was placed onto a quartz sample 
holder with the zero background and then air-dried to form a thin film for XRD pattern collection. 
Transmission electron microscopy (TEM) images were obtained on a JEOL 1010A transmission 
electron microscope at an acceleration voltage of 100 kV. The loading amount of 5-FU into LDH 
were determined by UV-Vis absorbance at 265 nm. Mg and Al contents in all samples were 
determined by inductive coupled plasma - atomic emission spectroscopy (ICP-AES) on a Varian 
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Vista Pro instrument. Element analysis of C, H and N was conducted using Flash EA 1112 
CHNS-O analyser (Thermo Electron Corp., US) 
 
2.5 Agarose gel electrophoresis 
The binding ability of CD-siRNA with 5-FU/LDH or LDH nanoparticles was evaluated by gel 
retardation. In this test, the mimic dsDNA was used instead of CD-siRNA. In typical gel 
retardation, 20 μL of dsDNA-5-FU/LDH nanocomplexes containing 200 ng of dsDNA was 
loaded into the well in a 2% agarose gel containing GelRed stain, followed by electrophoresis at 
80 V for 40 min. The gel was analyzed on a GelDoc UV illuminator (Biorad Laboratories) to 
show the position of the dsDNA band relative to that of free dsDNA.  
 
2.6 Cell culture and cellular uptake 
Human breast (MCF-7), osteosarcoma (U2OS) and colorectal (HCT-116) cancer cell lines were 
routinely cultured in a DMEM medium supplemented with 10% fetal calf serum and penicillin 
(10 U/mL)/streptomycin (10 μg/mL) in a humidified atmosphere at 37 oC under 5% CO2.  For 
cellular uptake, MCF-7 cells were seeded on the coverslips in a 6-well plate at a density of 1×106 
cells cm−2 and cultured for 24 h. Neg-siRNA AF546 was used to evaluate the cellular uptake of 
siRNA-5-FU/LDH nanocomplexes. After incubating for 24 h, 1 mL of red-free medium 
containing Neg-siRNA AF546-5-FU/LDH nanocomplexes was added into the plate and the cells 
were incubated for 4 h. Then, cells were washed twice with a PBS buffer, fixed and moved to the 
glass slides containing a DAPI mounting medium. After nucleus staining, the confocal images 
were taken on Carl Zeiss LSM 710 confocal laser scanning microscope AFM CLSM.   
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2.7 Cell viability test 
Cell viability was determined by the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. In all experiments, cancer cells (MCF-7, U2OS and HCT116) were 
seeded in 24-well plates at a density of 5 × 104 cells per well in 500 μL of culture medium and 
incubated for 24 h to allow cell attachment. Following the attachment, the cells were incubated 
in a fresh medium (500 μL/well) containing 5-FU, 5-FU/LDH, CD-siRNA-5-FU/LDH or CD-
siRNA/LDH at the 5-FU concentration ranging from 0.6 to 9.6 μg/mL and the siRNA 
concentration of 40 nM for 72 h. Then, 50 μL of 5 mg/ml MTT was added to each well. After 
incubating for 4 h in a dark room, the MTT containing medium was removed and 250 μL of 
DMSO was added to each well to dissolve the MTT formazan. Absorbance of converted dye was 
measured at 570 nm with a background subtraction at 650 nm using an ELISA plate reader (Bio-
Tek, USA). Cell viability was calculated using the following equation: Cell viability (%) = (𝐴𝑠 𝐴𝑐𝑜𝑛𝑡𝑟𝑜𝑙) × 100⁄  
where As was the absorbance of cells treated under various conditions and Acontrol was the 
absorbance of the cells in the standard medium.  
 
2.8 Apoptosis 
A FITC Annexin V Apoptosis Detection Kit I was used to identify the early apoptotic cells. 
MCF-7 cells were seeded in a 6-well plate at a density of 1×106 cells/well. After incubating for 
24 h, 1 mL of fresh medium containing 5-FU, LDH, 5-FU/LDH, CD-siRNA/LDH, CD-siRNA-
5-FU/LDH, or negative siRNA-5-FU/LDH was added to each well. After incubating for 24 h, the 
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cells were collected and stained with Annexin V conjugated FITC and PI according to the 
manufacturer’s instructions. The apoptotic and necrotic cells in the cell population were analyzed 
using the software Flow Jo.  
 
2.9 Western blotting 
MCF-7 cells were seeded in a 6-well plate at a density of 1×106 cells/well. After incubating for 
24 h, 1 mL of fresh medium containing 5-FU, LDH, 5-FU/LDH, CD-siRNA/LDH, CD-siRNA-
5-FU/LDH, or negative siRNA-5-FU/LDH was added to each well. After transfection for 24 h, 
the cells were collected for the western blotting test as described below.  
Treated cells were washed with chilled PBS buffer and lysed in ice-cold lysis buffer. The 
lysate samples were centrifuged at 40C for 10 mins at 15000g. The protein concentrations in 
lysates were determined with Bio-Rad DC Protein Assay kit according to the manufacturer’s 
recommended instructions. Equivalent amounts of protein (40 μg) from each cell lysate were 
separated on a pre-casting gel and transferred electrophoretically onto Hybond-ECL. The 
membranes were blocked with Tris-buffered saline containing 0.05% Tween 20 and 3% nonfat 
dry milk powder for 1 hour at room temperature and then incubated overnight at 4 °C with 
primary antibodies: mouse monoclonal anti-human Bcl-2 antibody and mouse monoclonal anti-
human α-tubulin antibody, respectively. α-tubulin was used as a loading control. Following three 
washes with Tris-buffered saline containing 0.05% Tween 20, membranes were incubated with 
horseradish peroxidase-conjugated goat anti-mouse secondary antibody (MP Biomedicals, Solon, 
OH) for 1 hour at room temperature. After an additional three washes with Tris-buffered saline 
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containing 0.05% Tween 20, membranes were analyzed on a GelDoc UV illuminator (Biorad 
Laboratories). 
 
2.10 Statistical analyses 
Data are presented as mean ± SEM and analyzed by one-way ANOVA with Bonferroni post-
tests using GraphPad Prism software; a p-value < 0.05 was considered statistically significant. 
 
3. Results and discussion 
3.1 Characteristics of 5-FU/LDH nanohybrids  
In our previous studies, homogeneous LDH-Cl nanoparticle suspension with the size of 
approximately 100 nm was prepared using the co-precipitation and hydrothermal treatment 
method [16]. Based on this method, we loaded 5-FU into LDH nanoparticles via the ion-
exchange process. Stable 5-FU/LDH nanohybrid suspension was obtained and the structural 
characteristics of 5-FU/LDH nanohybrids were examined. As shown in Fig. 1A, the XRD 
patterns of pristine LDH-Cl particles presented strong and symmetric (00l) reflections, 
corresponding to (003) and (006) and demonstrating the formation of crystalline layered 
compounds. The basal spacing of LDH-Cl was 0.76 nm, identical to the value reported in the 
literature [16]. In comparison, the (00l) reflections of 5-FU(10)/LDH nanohybrids became 
weaker and broader, suggesting the reduced crystallinity of the LDH phase. It appears that the 
(003) peak in 5-FU(50)/LDH nanohybrids was composed of two overlapping peaks at 12.3o and 
14.3o, respectively. The low-angle peak (12.3o) could be induced by the intercalation of 5-FU 
into LDH layers and the basal spacing of 5-FU(50)/LDH layered phase was determined to be 
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0.83 nm. As the thickness of the LDH-Cl layer is ~0.48 nm, the gallery height corresponding to 
the (003) peaks in 5-FU(50)/LDH is thus 0.35 nm, very close to the thickness of 5-FU (0.34 nm) 
[27], suggesting that 5-FU molecules are horizontally, not vertically, intercalated into the LDH 
interlayers [28], as shown in Scheme 1B. The horizontal intercalation of 5-FU into LDH is 
different from the observation by Xu et al. They observed that 5-FU was vertically intercalated 
into the LDH interlayer, where they used ammonia as the base to co-precipitate 5-FU with LDH 
[29]. 
As shown in Fig. 1B, 5-FU/LDH nanohybrids had a narrow particle size distribution in the 
range of 50-150 nm. Compared with LDH-Cl, the average size of 5-FU/LDH decreased from 109 
nm to 85 nm, as listed in Table 1. This is probably due to the inhibition of the hydroxide layer 
growth along the a and b axes by the anionic organic drug 5-FU, as proposed in the previous 
study [30]. The zeta potential was around +40.6 mV, close to that of LDH-Cl nanoparticles 
(+42.2 mV). The similarity in zeta potential probably indicates that 5-FU loading by means of 
ion exchange results in the similar surface charge and the similar dispersion state, suggesting a 
similar affinity of ionized 5-FU and Cl- for LDHs.  
As imaged in Fig. 1C, 5-FU(10)/LDH nanohybrids were plate-like particles of an almost 
hexagonal shape, similar to that of LDH-Cl [16]. The lateral dimension of 5-FU(10)/LDH in Fig. 
1C was found in the range of 50-150 nm, in good agreement with the DLS data in Fig. 1B.  
FT-IR spectra of 5-FU/LDH, LDH and pure sodium-5-FU (Na-5FU) samples are shown in 
Fig. 1D. The spectrum of LDH had strong bands at 767, 667 and 549 cm-1, corresponding to M–
O vibrations and M–O–H bending [26]. An additional peak at 1365 cm-1 was seen from LDH-Cl, 
resulting from some CO32- contamination [31]. As expected, these characteristic peaks of the 
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LDH phase also appeared in 5-FU(50)/LDH sample, suggesting its nature of LDH material. 
Since 5-FU exists in an ionic form in the LDH layer (Scheme 1B), we prepared Na-5FU samples 
by neutralizing with NaOH to pH 9 for the comparison in FT-IR spectra. Notably, two strong 
peaks at 1650 and 1540 cm-1, characteristic bands of Na-5FU, were tentatively assigned to the 
stretching vibrations of C=O and C=N bonds [32], which were clearly observed in 5-
FU(50)/LDH nanohybrids at 1675 and 1545 cm-1 (Fig. 1D). Moreover, the bands at 1220 cm-1, 
attributing to C-F stretching band for Na-5FU, was also shown in 5-FU(50)/LDH nanohybrids. 
This suggests that ionized 5-FU was successfully intercalated in the LDH interlayer.  
Element analysis confirms 5-FU loading into LDH and reveals the composition of as-obtained 
samples. As listed in Table 1, the loading amount of 5-FU in 5-FU(10)/LDH and 5-FU(50)/LDH 
was found 5.12 and 22.60 wt%, respectively. The Mg/Al atomic ratio from ICP measurement 
was 1.9~2.1, close to the nominal ratio (2.0). Based on these data, the chemical composition of 
LDHs, 5-FU(10)/LDH, and 5-FU(50)/LDH nanohybrids was approximately 
Mg1.9Al(OH)5.8(CO32-)0.05Cl0.9·1.5H2O, Mg2.1Al(OH)6.2(5-FU)0.1(1/2CO32-,Cl)0.9·1.5H2O and 
Mg2.1Al(OH)6.2(5-FU)0.5(1/2CO32-,Cl)0.5·1.5H2O, respectively. In the following studies, 5-
FU(10)/LDH sample was used for cell tests as its loading amount of 5-FU was sufficiently high.  
 
3.2 Binding capacity of siRNA for 5-FU/LDH nanohybrids 
To investigate whether and to what extent the 5-FU loading in the LDH layer has effect on 
siRNA-LDH interaction, the siRNA binding ability of 5-FU/LDH was investigated through the 
agarose gel retardation assay. Due to siRNA's intrinsic instability and high cost, mimic dsDNA 
with the same size and sequence was used in the experiment. As shown in Fig. 2, free dsDNA 
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migrated to the bottom and exhibited a bright band. Clearly, no bright dsDNA bands were 
observed at the bottom when the mass ratio of 5-FU/LDH to dsDNA was more than 10:1. Instead, 
the majority of the dsDNA remained in the loading well and a very small portion of associated 
dsDNA was dissociated and slowly migrated toward the bottom during electrophoresis, 
indicating retardation of DNA mobility due to neutralization of the dsDNA negative charge by 
the surface positive charge of 5-FU/LDH nanohybrids. When the mass ratio of 5-FU/LDH to 
dsDNA decreased to 5:1, a weak band was observed at the bottom, indicating a small amount of 
free DNA in the solution. This suggests that 5-FU/LDH nanohybrids can effectively bind with 
dsDNA at the mass ratio of LDH to dsDNA over 10:1.  
Compared to pristine LDH-Cl, 5-FU/LDH nanohybrids presented a similar dsDNA binding 
efficiency. As shown in Fig. S1, similar phenomena could be observed when LDH-Cl was used 
to bind the mimic dsDNA. The similarity in binding dsDNA could be explained by the 
comparable zeta potentials of 5-FU/LDH (+40.6 mV) and LDH-Cl (+42.2 mV), e.g. 5-FU/LDH 
nanohybrids and LDH-Cl nanoparticles display similar electrostatic interactions with dsDNA or 
siRNA. This further demonstrates that 5-FU loading has no obvious effect on the binding 
property of LDH-Cl. Therefore, LDH nanoparticles can simultaneously carry 5-FU and 
dsDNA/siRNA in a stable colloid at the mass ratio of LDH to dsDNA or siRNA over 10:1.  
 
3.3 Cellular uptake and intercellular localization 
The cellular internalization of siRNA and 5-FU into the cells was investigated by complexing 
LDH-Cl nanoparticles or 5-FU/LDH nanohybrids with red-flourescence negative control siRNA 
(Red siRNA 456). Cell nuclei were stained with DAPI. As shown in Fig. 3A and 3B, strong red 
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fluorescence was observed in the perinuclear region in the MCF-7 cytoplasm for both LDH-Cl 
and 5-FU/LDH with similar red fluorescence intensities (40 nM Red siRNA 546, the mass ratio 
of siRNA:LDH = 1:40, 4-h incubation). The similar red-fluorescent cells were also observed at 
the siRNA:LDH mass ratio of 1:20 (Fig. S2A and S2B). In contrast, no red fluorescence was 
observed in MCF-7 cells after incubating with free Red-siRNA 546 (data not shown here), which 
is consistent with our previous reports that free siRNA does not efficiently penetrate the plasma 
membrane [33]. These data clearly show that 5-FU/LDH nanohybrids are able to enter into 
cancer cells and simultaneously deliver 5-FU and siRNA into the cytoplasm, confirming our 
hypothesis that LDH can effectively co-deliver the anti-cancer drug and siRNA into the cancer 
cells.  
It is noteworthy that the red puncta shown in Fig. 4B are likely to be early endosomes and 
multivesicular bodies, which have previously been demonstrated as the internalization route for 
LDH nanoparticles [22, 25, 31, 34]. Thus, 5-FU/LDH entry into MCF-7  invovles a clathrin-
mediated time- and dose-dependent endocytosis [22, 25]. We further demonstrated in the present 
study that the endocytosis of 5-FU/LDH nanohybrids is an energy-dependent process by 
incubating cells at 4oC for 4 h after exposure to Red siRNA 546-5-FU/LDH or Red siRNA 
546/LDH. The confocal images in Fig. 3C and 3D show that there was no red fluorescence in the 
cytoplasm and the nucleus, indicating that cellular entry of 5-FU/LDH and LDH-Cl were 
significantly inhibited at 4oC. Therefore, LDH nanoparticles enter cells through an energy-
dependent endocytic mechanism.  
 Moreover, recent studies on cellular uptake meachanisms and cellular trafficking of LDH 
particles reveal that LDH cellular uptake undergoes a clathrin-mediated endocytosis pathway in 
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various cell lines [31, 34]. We reported that LDH has a unique capacity for ‘endosmal escape’ 
(similar to the proton sponge effect) and can buffer an endosomal/lysosomal environment (pH 4-
5) in virtue of partial dissolution of LDHs, thus allowing LDH to quickly escape from the 
endosome/lysosome and release loaded drugs/siRNA into the cytoplasm [31]. Therefore, the 
buffering property of LDH nanoparticles is supposed to promote the delivery of both siRNA and 
5-FU into MCF-7 cells, leading to the anticancer efficacy, as presented below.  
 
3.4 Cytotoxicity to cancer cells 
Firstly, the cytotoxicity of LDH-Cl nanocarriers to MCF-7 cells in the concentration range of 50 
- 200 μg/mL was examined. As shown in Fig. 4, the cell viability was all above 90% following a 
3-day incubation, suggesting that LDH nanoparticles do not induce acute cytotoxicity and are 
well compatible to cancer cells. This is consistent with our previous reports that LDH 
nanoparticles do not inhibit cell proliferation even at LDH concentrations up to 500 μg/mL in 
various cell lines [20-22, 25, 33]. Therefore, LDH nanoparticles could be safely used as a drug 
and gene delivery system.  
We then examined the cytotoxicity of 5-FU and 5-FU/LDH to MCF7 cells. As shown in Fig. 
5, treatment with 5-FU only decreased cell viability in a dose-dependent manner and ∼40% of 
MCF-7 cells died at 9.6 μg/mL, concurring with previous reports [35, 36]. Compared to free 5-
FU, 5-FU/LDH caused considerably more MCF7 cell death and decreased cell viability further 
by 20-30% at each concentration point in the range of 0.6-9.6 μg/mL, with cancer cell mortality 
over 60% at 2.4 μg/mL or higher concentrations of 5-FU. The enhancement of 5-FU cytotoxicity 
to cancer cells through LDH delivery has also been observed by Choy et al [20]. This 
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enhancement can be attributed to the more efficient cellular uptake of 5-FU mediated by LDH 
nanoparticles compared to 5-FU only, as reported for the cellular uptake of negatively charged 
FITC and dsDNA [31].  
Treatment with CD-siRNA only did not cause obvious cell death even at 80 nM in the 
medium (data not shown), mainly because the negative charge of siRNA limits its cellular uptake. 
When CD-siRNA was loaded with LDH and used to treat cells, ∼35% of MCF-7 cells were 
killed at 40 nM (Fig. 5). The enhanced cytotoxicity can be attributed to the offset of the negative 
charge of siRNA by positively charged LDH; therefore LDH can effectively deliver siRNA (Fig. 
4A) and suppress cell growth [25].  
Remarkably, a combination treatment of CD-siRNA and 5-FU, co-delivered by LDH, further 
decreased cell viability, particularly at the lower 5-FU concentrations (Fig. 5). For example, 
treatment with CD-siRNA-5-FU/LDH nanocomplexes (1.2 μg/mL of 5-FU and 40 nM of siRNA) 
caused ∼70% cell death, while treatment with either 5-FU/LDH or siRNA/LDH at the same 
concentration resulted in only 46% or 34% cell death. These data clearly show that a 
combination treatment with CD-siRNA and 5-FU with LDH nanoparticles significantly 
suppresses MCF-7 cell growth, probably a result of the synergistic effect of two therapeutics on 
cancer cells by effectively inducing cell death in complementary pathways [7, 37, 38].  
 To investigate whether cell death induced by 5-FU and CD siRNA is through early apoptosis, 
an Annexin V kit was used to analyze the early apoptosis after a 24-hour treatment. As shown in 
Fig. 6 (right bottom) and listed in Table 2, we did not see an obvious change in the cell 
population stained with Annexin V. Rather, we saw an increase in the cell population stained 
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with PI (left top in Fig. 6 and second line in Table 2). This suggests that early apoptosis or 
membrane damage was not the major pathway for the cell death caused by 5-FU and CD siRNA.  
As is well known, the overexpression of the antiapoptotic protein Bcl-2 is one of the major 
mechanisms by which various cancer cells acquire resistance to apoptosis and thereby resistance 
to chemotherapeutic agents such as 5-FU. Therefore, western blotting was further conducted to 
analyze anti-apoptosis protein Bcl-2. As shown in Fig. 7 and listed in Table 2, the combination 
treatment with CD siRNA-5-FU/LDH nanohybrids significantly decreased the level of Bcl-2, 
suggesting coordinate mitochondrial damage following treatment [10]. There may be a few 
possible ways to explain how 5-FU and CD siRNA can lead to Bcl-2 reduction [39]. One 
explanation relates to thymidine. It is known that 5-FU can interrupt the function of thymidylate 
synthase that blocks synthesis of the pyrimidine thymidine, which is a nucleoside required for 
DNA replication [36]. When the cells lack pyrimidine thymidine, the rapidly dividing cancerous 
cells die via a thymineless death [4]. In mitochondria, the lack of thymidine can also promote 
apoptosis. A previous study demonstrated that thymidine can attenuate adenosine-induced 
apoptosis by modulating the earliest stage of the mitochondrial apoptotic pathway [40], 
suggesting that certain levels of thymidine will protect mitochondria from apoptosis. Further 
studies may be needed to prove this. So far, the mechanism of CD siRNA causing cell death is 
not clear, and therefore no explanation can be given for its related Bcl-2 reduction. 
 
3.5 Applicability to other cell lines  
We have finally confirmed that our co-delivery strategy using LDH nanoparticles for effective 
cancer treatment can be applied to other cancer cell lines, such as U2OS and HCT-116. As 
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shown in Fig. S3A and S3B, a combination treatment of U2OS and HCT-116 cells with CD-
siRNA and 5-FU delivered by LDH resulted in significant suppression of cell growth compared 
to single treatment with either CD-siRNA/LDH or 5-FU/LDH alone. These results indicated that 
a combination treatment with CD-siRNA and 5-FU produced a synergistic inhibition effect on 
the cell growth of various cancers.  
 
4. Conclusions 
In summary, we have successfully developed a combined strategy that applies the LDH delivery 
system to simultaneously deliver CD-siRNA and chemotherapeutic drug 5-FU to cancer cells for 
effective cancer treatment. Our data clearly indicate that combination treatment with siRNA and 
5-FU co-delivered by LDHs can lead to significantly higher cytotoxicity to three cancer cell lines 
(MCF-7, U2OS and HCT-116) compared to the single treatment with either CD siRNA or 5-FU. 
Therefore, co-delivery of siRNAs and anticancer drugs by LDHs has great potential as a novel 
approach for effective cancer treatment.     
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Scheme 1 Schematic diagram of the LDH co-delivery system to co-load 5-FU and siRNA (A) 
and schematic illustration of the horizontal laying of 5-FU in the interlayer (B) 
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